You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

ANTARA (MICRONIZED) Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Antara (micronized) patents expire, and when can generic versions of Antara (micronized) launch?

Antara (micronized) is a drug marketed by Lupin and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has two patent family members in two countries.

The generic ingredient in ANTARA (MICRONIZED) is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Antara (micronized)

A generic version of ANTARA (MICRONIZED) was approved as fenofibrate by RHODES PHARMS on May 13th, 2005.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ANTARA (MICRONIZED)?
  • What are the global sales for ANTARA (MICRONIZED)?
  • What is Average Wholesale Price for ANTARA (MICRONIZED)?
Drug patent expirations by year for ANTARA (MICRONIZED)
Pharmacology for ANTARA (MICRONIZED)
Paragraph IV (Patent) Challenges for ANTARA (MICRONIZED)
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ANTARA (MICRONIZED) Capsules fenofibrate 43 mg and 130 mg 021695 1 2008-09-15

US Patents and Regulatory Information for ANTARA (MICRONIZED)

ANTARA (MICRONIZED) is protected by four US patents.

Patents protecting ANTARA (MICRONIZED)

Treating metabolic syndrome with fenofibrate
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING SEVERE HYPERTRIGLYCERIDEMIA

Treating metabolic syndrome with fenofibrate
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA

Reduced dose pharmaceutical compositions of fenofibrate
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA

Reduced dose pharmaceutical compositions of fenofibrate
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING SEVERE HYPERTRIGLYCERIDEMIA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lupin ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-004 Oct 18, 2013 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lupin ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-002 Nov 30, 2004 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lupin ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-001 Nov 30, 2004 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lupin ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-005 Oct 18, 2013 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Lupin ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-005 Oct 18, 2013 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Lupin ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-003 Nov 30, 2004 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ANTARA (MICRONIZED)

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lupin ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-002 Nov 30, 2004 ⤷  Sign Up ⤷  Sign Up
Lupin ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-001 Nov 30, 2004 ⤷  Sign Up ⤷  Sign Up
Lupin ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-003 Nov 30, 2004 ⤷  Sign Up ⤷  Sign Up
Lupin ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-001 Nov 30, 2004 ⤷  Sign Up ⤷  Sign Up
Lupin ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-003 Nov 30, 2004 ⤷  Sign Up ⤷  Sign Up
Lupin ANTARA (MICRONIZED) fenofibrate CAPSULE;ORAL 021695-001 Nov 30, 2004 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ANTARA (MICRONIZED)

See the table below for patents covering ANTARA (MICRONIZED) around the world.

Country Patent Number Title Estimated Expiration
Slovenia 1574214 ⤷  Sign Up
Ukraine 72925 ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО МІСТИТЬ ФЕНОФІБРАТ, І СПОСІБ ЇЇ ОДЕРЖАННЯ (ВАРІАНТИ);ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ФЕНОФИБРАТ, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ (ВАРИАНТЫ) (FENOFIBRATE-CONTAINING PHARMACEUTICAL COMPOSITION AND METHOD FOR ITS PREPARATION (VARIANTS)) ⤷  Sign Up
Greece 3004698 ⤷  Sign Up
Japan S6348212 FENOFIBRATE-CONTAINING GRANULAR MEDICINE AND MANUFACTURE ⤷  Sign Up
Brazil PI0414860 composição farmacêutica contendo fenofibrato e método para a preparação desta ⤷  Sign Up
Canada 2540235 COMPOSITION PHARMACEUTIQUE CONTENANT DU FENOFIBRATE ET SON PROCEDE DE PREPARATION (PHARMACEUTICAL COMPOSITION CONTAINING FENOFIBRATE AND METHODFOR THE PREPARATION THEREOF) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.